Cargando…
CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are...
Autores principales: | Bobrowicz, Malgorzata, Kubacz, Matylda, Slusarczyk, Aleksander, Winiarska, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765243/ https://www.ncbi.nlm.nih.gov/pubmed/33333768 http://dx.doi.org/10.3390/ijms21249531 |
Ejemplares similares
-
Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
por: Kusowska, Aleksandra, et al.
Publicado: (2022) -
The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era
por: Miazek-Zapala, Nina, et al.
Publicado: (2021) -
In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies
por: Kubacz, Matylda, et al.
Publicado: (2022) -
P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA
por: Kusowska, Aleksandra, et al.
Publicado: (2023) -
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
por: Bobrowicz, Malgorzata, et al.
Publicado: (2019)